Literature DB >> 23032694

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.

L Sokol, L Cripe, H Kantarjian, M A Sekeres, S Parmar, P Greenberg, S L Goldberg, V Bhushan, J Shammo, R Hohl, A Verma, G Garcia-Manero, Y-P Li, A Lowe, J Zhu, A F List.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23032694     DOI： 10.1038/leu.2012.264

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

Review 1.  The inflammatory microenvironment in MDS.

Authors:  Lili Yang; Yaqin Qian; Erika Eksioglu; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Cell Mol Life Sci       Date:  2015-02-08       Impact factor: 9.261

Review 2.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

3.  Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

Authors:  Simrit Parmar; Xiaoying Liu; Shawndeep S Tung; Simon N Robinson; Gabriel Rodriguez; Laurence J N Cooper; Hui Yang; Nina Shah; Hong Yang; Marina Konopleva; Jeffery J Molldrem; Guillermo Garcia-Manero; Amer Najjar; Eric Yvon; Ian McNiece; Katy Rezvani; Barbara Savoldo; Catherine M Bollard; Elizabeth J Shpall
Journal:  Cytotherapy       Date:  2013-10-26       Impact factor: 5.414

Review 4.  Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.

Authors:  Kathryn S Ivy; P Brent Ferrell
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

5.  JNK, p38, ERK, and SGK1 Inhibitors in Cancer.

Authors:  Jonas Cicenas; Egle Zalyte; Arnas Rimkus; Dalius Dapkus; Remigijus Noreika; Sigitas Urbonavicius
Journal:  Cancers (Basel)       Date:  2017-12-21       Impact factor: 6.639

Review 6.  Research advances in kinase enzymes and inhibitors for cardiovascular disease treatment.

Authors:  Rand Shahin; Omar Shaheen; Faris El-Dahiyat; Maha Habash; Sana Saffour
Journal:  Future Sci OA       Date:  2017-08-08

7.  An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614).

Authors:  Lance A Wollenberg; Donald T Corson; Courtney A Nugent; Farran L Peterson; Ann M Ptaszynski; Alisha Arrigo; Coralee G Mannila; Kevin S Litwiler; Stacie J Bell
Journal:  Clin Pharmacol       Date:  2015-09-30

Review 8.  Signal transduction inhibitors in treatment of myelodysplastic syndromes.

Authors:  Lohith Bachegowda; Oleg Gligich; Ionnis Mantzaris; Carolina Schinke; Dale Wyville; Tatiana Carrillo; Ira Braunschweig; Ulrich Steidl; Amit Verma
Journal:  J Hematol Oncol       Date:  2013-07-10       Impact factor: 17.388

9.  Immunological derangement in hypocellular myelodysplastic syndromes.

Authors:  B Serio; Am Risitano; V Giudice; N Montuori; C Selleri
Journal:  Transl Med UniSa       Date:  2014-02-04

10.  Effect of a p38 MAPK inhibitor on FFA-induced hepatic insulin resistance in vivo.

Authors:  S Pereira; W Q Yu; J Moore; Y Mori; E Tsiani; A Giacca
Journal:  Nutr Diabetes       Date:  2016-05-02       Impact factor: 5.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.